Verastem Oncology Reports $18.7M Revenue from AVMAPKI FAKZYNJA CO-PACK, Advances VS-7375 Trials
Event summary
- Verastem Oncology reported $18.7M in net product revenue from AVMAPKI FAKZYNJA CO-PACK in Q1 2026, up from $0 in Q1 2025.
- The company initiated three Phase 2 registration-directed trials for VS-7375 in pancreatic, lung, and colorectal cancers.
- GenFleet Therapeutics received Breakthrough Therapy Designation for VS-7375 in China for KRAS G12D-mutated pancreatic and lung cancers.
- Verastem appointed Daniel Lyons as Chief Commercial Officer, formerly of SpringWorks Therapeutics.
The big picture
Verastem Oncology is balancing commercialization of its first approved product with aggressive clinical development of VS-7375, a potential blockbuster KRAS G12D inhibitor. The company's progress comes amid a competitive landscape for RAS/MAPK pathway-driven cancer therapies, where strategic partnerships and regulatory designations in key markets like China could differentiate its pipeline. With $181.7M in cash as of Q1 2026, Verastem has runway to execute its dual strategy, but must demonstrate sustained revenue growth and clinical efficacy to justify its valuation.
What we're watching
- Commercial Execution
- Whether Verastem can sustain revenue growth from AVMAPKI FAKZYNJA CO-PACK amid competitive pressures in the rare cancer space.
- Clinical Development
- The pace at which VS-7375 advances through Phase 2 trials and whether early data supports its potential as a best-in-class KRAS G12D inhibitor.
- Regulatory Strategy
- How Verastem navigates the FDA's requests for separate Phase 2 trial protocols and the potential impact on timelines.
Related topics